drugset / Trial / NCT03670095

Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions

NCT03670095

Phase 1 Completed 64 enrolled H. Lundbeck A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the release of memantine into the bloodstream of two different formulations: one formulation containing lactose and one without lactose.

Timeline

Start
2018-08-28
Primary completion
2018-12-24
Completion
2018-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral

Indications

No indication recorded.